BUZZ-Organon rises after US FDA clears first biosimilar for breast cancer
I'm PortAI, I can summarize articles.
Shares of healthcare firm Organonrise 4.65% to $7.88 premarketCo and Shanghai Henlius Biotech say US FDA approves their breast cancer drug PoherdyThe two companies’ Poherdy first biosimilar to rival Roche’s (ROG.S) Perjeta for HER2-positive breast cancer - OGNCo says drug to be used with other therapies for advanced or early-stage breast cancer; Organon to market in U.S - OGNPoherdy carries warnings for heart issues and birth defects; doctors advised to monitor patients, co saysUp to last close, stock down ~50% YTD
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments